Trisalus Life Sciences, Inc.
Clinical trials sponsored by Trisalus Life Sciences, Inc., explained in plain language.
-
Targeted attack: new method pumps Immune-Boosting drug directly to liver tumors
Disease control TerminatedThis early-phase study tested a new way to treat advanced liver cancer. It delivered an experimental immune-stimulating drug (SD-101) directly into the liver's main artery, sometimes combined with standard immunotherapy drugs given by IV. The goal was to see if this targeted appr…
Phase: PHASE1, PHASE2 • Sponsor: TriSalus Life Sciences, Inc. • Aim: Disease control
Last updated Apr 04, 2026 06:35 UTC
-
New hope for rare eye cancer that spreads to the liver
Disease control TerminatedThis early-stage study tested a new drug called SD-101, delivered directly to the liver, for adults with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if SD-101 was safe and tolerable when given alone or combined with standard immunotherapy …
Phase: PHASE1 • Sponsor: TriSalus Life Sciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC